Safety and Efficacy of Nanocurcumin as Add-On Therapy to Riluzole in Patients With Amyotrophic Lateral Sclerosis: A Pilot Randomized Clinical Trial

The objective of present study was to assess the safety and efficacy of nanocurcumin as an anti-inflammatory and antioxidant agent in adults with amyotrophic lateral sclerosis (ALS). We conducted a 12-month, double-blind, randomized, placebo-controlled trial at a neurological referral center in Iran...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neurotherapeutics
Autors principals: Ahmadi, Mona, Agah, Elmira, Nafissi, Shahriar, Jaafari, Mahmoud Reza, Harirchian, Mohammad Hossein, Sarraf, Payam, Faghihi-Kashani, Sara, Hosseini, Seyed Jalal, Ghoreishi, Abdolreza, Aghamollaii, Vajiheh, Hosseini, Mostafa, Tafakhori, Abbas
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2018
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5935637/
https://ncbi.nlm.nih.gov/pubmed/29352425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13311-018-0606-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars